We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting Angiogenesis with Multitargeted Tyrosine Kinase Inhibitors in the Treatment of Non-Small Cell Lung Cancer.
- Authors
Scagliotti, Giorgio; Govindan, Ramaswamy
- Abstract
It has been >35 years since the link between angiogenesis and the growth of tumors was first reported. Targeting angiogenesis became feasible with the availability of bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody. Initial studies revealed that the combination of bevacizumab and chemotherapy led to longer overall survival times than with chemotherapy alone in patients with advanced colorectal cancer. Since then, drug development strategies have added small molecule tyrosine kinase inhibitors to the panel of antiangiogenic agents under evaluation; data from numerous trials are now available. The challenge now is to identify the optimal antiangiogenic agent for specific patient groups and to understand not only the mechanistic differences between agents, but also the variability in their antitumor activity across different tumor types and their differing side-effect profiles. As in other solid tumors, angiogenesis contributes to the development of non-small cell lung cancer (NSCLC), and this review summarizes the role of angiogenesis in this disease. We review the current developmental status of antiangiogenic tyrosine kinase inhibitors (including vandetanib, sunitinib, axitinib, sorafenib, vatalanib,and pazopanib) in NSCLC and conclude by briefly discussing the need for optimal patient selection and potential future directions.
- Subjects
NEOVASCULARIZATION; PROTEIN-tyrosine kinases; SMALL cell lung cancer; CANCER treatment; BEVACIZUMAB; DRUG therapy; MONOCLONAL antibody probes; VASCULAR endothelial growth factors; COLON cancer
- Publication
Oncologist, 2010, Vol 15, Issue 5, p436
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1634/theoncologist.2009-0225